Lake Street Capital Lowers Sensus Healthcare (NASDAQ:SRTS) Price Target to $13.00

Sensus Healthcare (NASDAQ:SRTS) had its price target decreased by stock analysts at Lake Street Capital from $18.00 to $13.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price objective would indicate a potential upside of 196.47% from the stock’s previous close.

A number of other equities research analysts have also issued reports on SRTS. Maxim Group boosted their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a report on Friday, November 15th. HC Wainwright lifted their price objective on shares of Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, February 10th.

Sensus Healthcare Trading Up 0.8 %

Shares of NASDAQ SRTS traded up $0.04 during mid-day trading on Tuesday, reaching $4.39. The company had a trading volume of 60,184 shares, compared to its average volume of 367,445. The company has a 50-day moving average price of $6.23 and a two-hundred day moving average price of $6.71. The stock has a market cap of $72.33 million, a PE ratio of 10.94 and a beta of 1.28. Sensus Healthcare has a 1-year low of $2.91 and a 1-year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. On average, research analysts expect that Sensus Healthcare will post 0.32 EPS for the current year.

Hedge Funds Weigh In On Sensus Healthcare

A number of large investors have recently made changes to their positions in SRTS. Dimensional Fund Advisors LP boosted its holdings in shares of Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock worth $2,620,000 after purchasing an additional 88,953 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of Sensus Healthcare by 81.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock valued at $1,039,000 after buying an additional 67,269 shares during the period. Marshall Wace LLP grew its holdings in shares of Sensus Healthcare by 99.6% during the 4th quarter. Marshall Wace LLP now owns 132,286 shares of the company’s stock valued at $915,000 after acquiring an additional 65,994 shares in the last quarter. Millennium Management LLC increased its stake in shares of Sensus Healthcare by 256.6% in the fourth quarter. Millennium Management LLC now owns 85,329 shares of the company’s stock worth $590,000 after acquiring an additional 61,403 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Sensus Healthcare in the fourth quarter worth $381,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.